Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 143.00 | |
5 mg | In stock | $ 363.00 | |
10 mg | In stock | $ 543.00 | |
25 mg | In stock | $ 877.00 | |
50 mg | In stock | $ 1,180.00 | |
100 mg | In stock | $ 1,620.00 | |
500 mg | In stock | $ 3,250.00 |
Description | SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression. |
Targets&IC50 | PI3Kγ:11100 nM (IC50), PI3Kα:861 nM (IC50), ZAP70:1300 nM (IC50), Syk:10.7 nM (IC50), PI3Kδ:1280 nM (IC50) |
In vitro | The IC50 values are 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 (10 μmol/L) blocks p-AKT[1]. |
In vivo | Oral administration of SRX3207 increases antitumor immune response. SRX3207 blocks immunosuppressive MΦ polarization, blocks tumor growth, and increases survival effectively[1]. |
Molecular Weight | 555.65 |
Formula | C29H29N7O3S |
CAS No. | 2254693-15-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.5 mg/mL (8.1 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SRX3207 2254693-15-5 Angiogenesis Others PI3K/Akt/mTOR signaling Tyrosine Kinase/Adaptors PI3K Syk SRX 3207 SRX-3207 inhibitor inhibit